These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 25783505)

  • 21. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
    Gupta SK; Singla S; Bal C
    Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High clinical and morphologic response using
    Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival predictors of
    Swiha MM; Sutherland DEK; Sistani G; Khatami A; Abazid RM; Mujoomdar A; Wiseman DP; Romsa JG; Reid RH; Laidley DT
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):225-236. PubMed ID: 34110489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
    Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
    Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of
    Zhang J; Song Q; Cai L; Xie Y; Chen Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event.
    Karfis I; Marin G; Machiels G; Hendlisz A; Flamen P
    Clin Nucl Med; 2018 Jul; 43(7):e232-e233. PubMed ID: 29762236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Efficacy, Survival, and Safety of [
    Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
    Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
    [No Abstract]   [Full Text] [Related]  

  • 29. Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors.
    Vida Navas EM; Martínez Lorca A; Sancho Gutiérrez A; Sanz Gómez L; Navarro Martínez T; Grande Pulido E; Carrato Mena A; Gajate Borau P
    Front Endocrinol (Lausanne); 2021; 12():676973. PubMed ID: 33935979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged response to
    Cottereau AS; Bricaire L; Arrondeau J; Dechmi A; Montravers F; Coriat R; Clerc J; Groussin L; Tenenbaum F
    Invest New Drugs; 2020 Aug; 38(4):1196-1199. PubMed ID: 31650444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twins in spirit part IV - [
    Brogsitter C; Hartmann H; Wunderlich G; Schottelius M; Wester HJ; Kotzerke J
    Nuklearmedizin; 2017 Feb; 56(1):1-8. PubMed ID: 28138688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
    Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
    Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
    J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
    Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
    Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
    Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
    Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of receptor radionuclide therapy with
    Nicolini S; Severi S; Ianniello A; Sansovini M; Ambrosetti A; Bongiovanni A; Scarpi E; Di Mauro F; Rossi A; Matteucci F; Paganelli G
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):923-930. PubMed ID: 29387927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
    Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
    Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radionuclide Therapy for Neuroendocrine Tumors.
    Cives M; Strosberg J
    Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.